SEMNUR PHARMACEUTICALS, INC.
SMNR evidence brief
What we can confirm
- BioSniper Score:
- 2.5 / 10
- Market Cap:
- $115.1M
- Next Catalyst:
- Phase3_Start · Feb 1, 2027
What it means
What to watch
Prepared research question
What matters most for SMNR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SMNR
Semnur Pharmaceuticals is a late-stage clinical biopharmaceutical company developing non-opioid pain management therapies, with its lead candidate SP-102 targeting a potential first-in-class FDA approval for radicular pain.
Key risk: Cash depletion and negative equity
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial · 1 catalyst for SEMNUR PHARMACEUTICALS, INC..
Semnur Pharmaceuticals is a late-stage clinical biopharmaceutical company developing non-opioid pain management therapies, with its lead candidate SP-102 targeting a potential first-in-class FDA approval for radicular pain.
- Semnur is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for acute and chronic pain [sec_mda · as of 2026-05-13].
- Lead product candidate SP-102 (dexamethasone sodium phosphate viscous gel) has completed a pivotal Phase 3 study and, if approved, could become the first FDA-approved non-opioid epidural steroid for radicular pain [sec_mda · as of 2026-02-27].
- As of June 30, 2026, the company reported cash and equivalents of $0.0M, net income of -$4.3M, shareholders' equity of -$29.7M, and total debt of $6.1M [sec].
- The company plans to initiate a Phase 3 trial (C.L.E.A.R 2) for SP-102 on February 1, 2027, with a targeted commercial launch in 2028 [catalyst][sec_mda · as of 2026-02-27].
- Semnur was acquired by Scilex Holding Company in 2019 and became a stand-alone public company after separation from Scilex [sec_mda · as of 2026-02-27].
What works
- SP-102 targets a large market opportunity with high unmet need for non-opioid pain therapies, and the company has completed a pivotal Phase 3 study [sec_mda · as of 2026-02-27].
- The management team has extensive experience in pain and neurology, with a track record of commercializing pain management products [sec_mda · as of 2026-02-27].
- Semnur plans to leverage Scilex's commercial infrastructure for potential launch, including negotiations with insurers and distribution agreements [sec_mda · as of 2026-02-27].
What to weigh
- As of June 30, 2026, the company had no cash and equivalents, negative shareholders' equity of -$29.7M, and total debt of $6.1M, indicating significant financial strain [sec].
- SP-102 has not yet received FDA approval, and the company faces risks inherent in clinical development and regulatory review [sec_mda · as of 2026-08-10].
- The company has not pursued substantive development beyond SP-102, making it heavily dependent on a single product candidate [sec_mda · as of 2026-02-27].
From the filings
Quoted directly from source documents.
Semnur is a late-stage clinical biopharmaceutical company focused on non-opioid pain management.
“We are a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain.”
SEC MD&A · May 13, 2026
Catalyst timeline
- 2027-02-01 · Phase3_Start: Corticosteroid Lumbar Epidural Analgesia for Radicular Pain (C.L.E.A.R) 2 - A Randomized, Double-blind, Active Comparator and Placebo-controlled, Multicenter, Safety and Efficacy Trial of SP-102 — Initiation of a pivotal Phase 3 trial for SP-102; enrollment and data will determine the path to NDA submission.
Risks & what to watch (4)›
Key risks
- Cash depletion and negative equity — As of June 30, 2026, cash was $0.0M and shareholders' equity was -$29.7M, raising going-concern risk [sec].
- Single product dependency — SP-102 is the only product candidate; failure would leave no pipeline [sec_mda · as of 2026-02-27].
- Regulatory and clinical uncertainty — SP-102 requires FDA approval; Phase 3 trial results and NDA review carry inherent risks [sec_mda · as of 2026-08-10].
- Debt burden — Total debt of $6.1M as of June 30, 2026, adds financial pressure [sec].
What to watch
- Initiation and enrollment of the Phase 3 CLEAR-2 trial for SP-102, expected to start February 1, 2027 [catalyst].
- Any updates on cash position or financing activities, given the zero cash balance as of June 30, 2026 [sec].
- Progress toward NDA submission and potential FDA approval, with a targeted commercial launch in 2028 [sec_mda · as of 2026-02-27].
- Partnership or distribution agreements for SP-102, including negotiations with insurers and third-party logistics providers [sec_mda · as of 2026-02-27].
Sources: Catalysts · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run SEMNUR PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SEMNUR PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$4M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~110d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for SEMNUR PHARMACEUTICALS, INC.?
Semnur Pharmaceuticals is a late-stage clinical biopharmaceutical company developing non-opioid pain management therapies, with its lead candidate SP-102 targeting a potential first-in-class FDA approval for radicular pain.
What is SEMNUR PHARMACEUTICALS, INC.'s next catalyst?
SEMNUR PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: Corticosteroid Lumbar Epidural Analgesia for Radicular Pain (C.L.E.A.R) 2 - A Randomized, Double-blind, Active Comparator and Placebo-controlled, Multicenter, Safety and Efficacy Trial of SP-102" — expected February 1, 2027.
Who is the CEO of SEMNUR PHARMACEUTICALS, INC.?
Dr. Henry H. Ji Ph.D. is the chief executive officer of SEMNUR PHARMACEUTICALS, INC. (SMNR).
Where is SEMNUR PHARMACEUTICALS, INC. headquartered?
SEMNUR PHARMACEUTICALS, INC. (SMNR) is headquartered in Palo Alto, CA, United States.
What therapeutic areas does SEMNUR PHARMACEUTICALS, INC. focus on?
SEMNUR PHARMACEUTICALS, INC. develops therapies across Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.